 | • レポートコード：MRC2304I0173 • 出版社/出版日：Persistence Market Research / 2023年1月31日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査資料では、世界の高効能医薬品有効成分（API）市場について調査・分析を行い、市場の現状と今後の展望を整理しています。本書は、エグゼクティブサマリー、市場概要、市場リスク・動向分析、市場背景、主要成功要因、需要分析・予測、価値分析、製品別（合成、バイオ）分析、製造業者別（インハウス、アウトソーシング）分析、医薬品別（革新的、ジェネリック）分析、用途別（腫瘍、ホルモンの乱れ、緑内障、その他）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ）分析、市場構造分析、競争分析、仮定、調査手法など、以下の構成で掲載しています。また、BASF SE、CordenPharma、Dr. Reddy’s Laboratories Ltd.、CARBOGEN AMCIS AG、Pfizer, Inc.、Sun Pharmaceutical Industries, Ltd.、Teva Pharmaceutical Industries Ltd.、Albany Molecular Research, Inc.、Sanofi S.A.、Merck & Co., Inc.、Novartis AG、F. Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、Boehringer Ingelheim International GmbH、Cipla Inc.などの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・市場リスク・動向分析 ・市場背景 ・主要成功要因 ・需要分析・予測 ・価値分析 ・世界の高効能医薬品有効成分（API）市場規模：製品別 - 合成高性能医薬品有効成分の市場規模 - バイオ高性能医薬品有効成分の市場規模 ・世界の高効能医薬品有効成分（API）市場規模：製造業者別 - インハウスにおける市場規模 - アウトソーシングにおける市場規模 ・世界の高効能医薬品有効成分（API）市場規模：医薬品別 - 革新的高性能医薬品有効成分の市場規模 - ジェネリック高性能医薬品有効成分の市場規模 ・世界の高効能医薬品有効成分（API）市場規模：用途別 - 腫瘍における市場規模 - ホルモンの乱れにおける市場規模 - 緑内障における市場規模 - その他用途における市場規模 ・世界の高効能医薬品有効成分（API）市場規模：地域別 - 北米の高効能医薬品有効成分（API）市場規模 - 中南米の高効能医薬品有効成分（API）市場規模 - ヨーロッパの高効能医薬品有効成分（API）市場規模 - アジア太平洋の高効能医薬品有効成分（API）市場規模 - 中東・アフリカの高効能医薬品有効成分（API）市場規模 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
High Potency Active Pharmaceutical Ingredients Market- Scope of Report
A recent study by Persistence Market Research on the High Potency Active Pharmaceutical Ingredients market offers a 10-year forecast for 2023 to 2033. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering High Potency Active Pharmaceutical Ingredients.
The study also provides the dynamics responsible for influencing the future status of the High Potency Active Pharmaceutical Ingredients market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.
A list of prominent companies operating in the High Potency Active Pharmaceutical Ingredients market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.
Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of High Potency Active Pharmaceutical Ingredients across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of High Potency Active Pharmaceutical Ingredients during the forecast period. Price point comparison by region with global average price is also considered in the study.
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for High Potency Active Pharmaceutical Ingredients and the High Potency Active Pharmaceutical Ingredients market are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report. Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global High Potency Active Pharmaceutical Ingredients Market.
Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the High Potency Active Pharmaceutical Ingredients market during the forecast period.
Country-specific valuation on demand for High Potency Active Pharmaceutical Ingredients has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.
In-depth Analysis on Competition
The report sheds light on leading players of High Potency Active Pharmaceutical Ingredients market along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering High Potency Active Pharmaceutical Ingredients has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the High Potency Active Pharmaceutical Ingredients domain.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage
2.2. Market Definition
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on High Potency Active Pharmaceutical Ingredients
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Mn)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. High Potency Active Pharmaceutical Ingredients Market, by Key Countries
4.2. High Potency Active Pharmaceutical Ingredients Market Opportunity Assessment (US$ Mn)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors – Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Growth in Automation, By Country
4.5.3. High Potency Active Pharmaceutical Ingredients Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. High Potency Active Pharmaceutical Ingredients Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global High Potency Active Pharmaceutical Ingredients Market Demand Analysis 2018-2022 and Forecast, 2023-2033
6.1. Historical Market Analysis, 2018-2022
6.2. Current and Future Market Projections, 2023-2033
6.3. Y-o-Y Growth Trend Analysis
7. Global High Potency Active Pharmaceutical Ingredients Market Value Analysis 2018-2022 and Forecast, 2023-2033
7.1. Historical Market Value (US$ Mn) Analysis, 2018-2022
7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033, By Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2018-2022
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2023-2033
8.3.1. Synthetic
8.3.2. Biotech
8.4. Market Attractiveness Analysis By Product Type
9. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033, By Manufacturer Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Manufacturer Type, 2018-2022
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Manufacturer Type, 2023-2033
9.3.1. In-house
9.3.2. Outsourced
9.4. Market Attractiveness Analysis By Manufacturer Type
10. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2018-2022
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Type, 2023-2033
10.3.1. Innovative
10.3.2. Generic
10.4. Market Attractiveness Analysis By Drug Type
11. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033, By Application
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Application, 2018-2022
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2023-2033
11.3.1. Oncology
11.3.2. Hormonal Disorders
11.3.3. Glaucoma
11.3.4. Other Applications
11.4. Market Attractiveness Analysis By Application
12. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2022
12.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2023-2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. Asia Pacific
12.3.5. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2023-2033
13.4.1. By Country
13.4.1.1. U.S.
13.4.1.2. Canada
13.4.1.3. Rest of North America
13.4.2. By Product Type
13.4.3. By Manufacturer Type
13.4.4. By Application
13.4.5. By Drug Type
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Product Type
13.5.3. By Manufacturer Type
13.5.4. By Application
13.5.5. By Drug Type
14. Latin America High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2023-2033
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Rest of Latin America
14.4.2. By Product Type
14.4.3. By Manufacturer Type
14.4.4. By Application
14.4.5. By Drug Type
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Product Type
14.5.3. By Manufacturer Type
14.5.4. By Application
14.5.5. By Drug Type
15. Europe High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
15.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2023-2033
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. France
15.4.1.3. U.K.
15.4.1.4. Italy
15.4.1.5. Benelux
15.4.1.6. Nordic Countries
15.4.1.7. Rest of Europe
15.4.2. By Product Type
15.4.3. By Manufacturer Type
15.4.4. By Application
15.4.5. By Drug Type
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Product Type
15.5.3. By Manufacturer Type
15.5.4. By Application
15.5.5. By Drug Type
16. Asia Pacific High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
16.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2023-2033
16.4.1. By Country
16.4.1.1. China
16.4.1.2. Japan
16.4.1.3. South Korea
16.4.1.4. Rest of Asia Pacific
16.4.2. By Product Type
16.4.3. By Manufacturer Type
16.4.4. By Application
16.4.5. By Drug Type
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Product Type
16.5.3. By Manufacturer Type
16.5.4. By Application
16.5.5. By Drug Type
17. Middle East and Africa High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
17.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2023-2033
17.4.1. By Country
17.4.1.1. GCC Countries
17.4.1.2. South Africa
17.4.1.3. Turkey
17.4.1.4. Rest of Middle East and Africa
17.4.2. By Product Type
17.4.3. By Manufacturer Type
17.4.4. By Application
17.4.5. By Drug Type
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Product Type
17.5.3. By Manufacturer Type
17.5.4. By Application
17.5.5. By Drug Type
18. Key Countries High Potency Active Pharmaceutical Ingredients Market Analysis 2018-2022 and Forecast 2023-2033
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. US High Potency Active Pharmaceutical Ingredients Market Analysis
18.2.1. Value Proportion Analysis by Market Taxonomy
18.2.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.2.2.1. By Product Type
18.2.2.2. By Manufacturer Type
18.2.2.3. By Application
18.2.2.4. By Drug Type
18.3. Canada High Potency Active Pharmaceutical Ingredients Market Analysis
18.3.1. Value Proportion Analysis by Market Taxonomy
18.3.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.3.2.1. By Product Type
18.3.2.2. By Manufacturer Type
18.3.2.3. By Application
18.3.2.4. By Drug Type
18.4. Mexico High Potency Active Pharmaceutical Ingredients Market Analysis
18.4.1. Value Proportion Analysis by Market Taxonomy
18.4.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.4.2.1. By Product Type
18.4.2.2. By Manufacturer Type
18.4.2.3. By Application
18.4.2.4. By Drug Type
18.5. Brazil High Potency Active Pharmaceutical Ingredients Market Analysis
18.5.1. Value Proportion Analysis by Market Taxonomy
18.5.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.5.2.1. By Product Type
18.5.2.2. By Manufacturer Type
18.5.2.3. By Application
18.5.2.4. By Drug Type
18.6. Germany High Potency Active Pharmaceutical Ingredients Market Analysis
18.6.1. Value Proportion Analysis by Market Taxonomy
18.6.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.6.2.1. By Product Type
18.6.2.2. By Manufacturer Type
18.6.2.3. By Application
18.6.2.4. By Drug Type
18.7. France High Potency Active Pharmaceutical Ingredients Market Analysis
18.7.1. Value Proportion Analysis by Market Taxonomy
18.7.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.7.2.1. By Product Type
18.7.2.2. By Manufacturer Type
18.7.2.3. By Application
18.7.2.4. By Drug Type
18.8. Italy High Potency Active Pharmaceutical Ingredients Market Analysis
18.8.1. Value Proportion Analysis by Market Taxonomy
18.8.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.8.2.1. By Product Type
18.8.2.2. By Manufacturer Type
18.8.2.3. By Application
18.8.2.4. By Drug Type
18.9. BENELUX High Potency Active Pharmaceutical Ingredients Market Analysis
18.9.1. Value Proportion Analysis by Market Taxonomy
18.9.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.9.2.1. By Product Type
18.9.2.2. By Manufacturer Type
18.9.2.3. By Application
18.9.2.4. By Drug Type
18.10. UK High Potency Active Pharmaceutical Ingredients Market Analysis
18.10.1. Value Proportion Analysis by Market Taxonomy
18.10.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.10.2.1. By Product Type
18.10.2.2. By Manufacturer Type
18.10.2.3. By Application
18.10.2.4. By Drug Type
18.11. Nordic Countries High Potency Active Pharmaceutical Ingredients Market Analysis
18.11.1. Value Proportion Analysis by Market Taxonomy
18.11.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.11.2.1. By Product Type
18.11.2.2. By Manufacturer Type
18.11.2.3. By Application
18.11.2.4. By Drug Type
18.12. China High Potency Active Pharmaceutical Ingredients Market Analysis
18.12.1. Value Proportion Analysis by Market Taxonomy
18.12.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.12.2.1. By Product Type
18.12.2.2. By Manufacturer Type
18.12.2.3. By Application
18.12.2.4. By Drug Type
18.13. Japan High Potency Active Pharmaceutical Ingredients Market Analysis
18.13.1. Value Proportion Analysis by Market Taxonomy
18.13.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.13.2.1. By Product Type
18.13.2.2. By Manufacturer Type
18.13.2.3. By Application
18.13.2.4. By Drug Type
18.14. South Korea High Potency Active Pharmaceutical Ingredients Market Analysis
18.14.1. Value Proportion Analysis by Market Taxonomy
18.14.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.14.2.1. By Product Type
18.14.2.2. By Manufacturer Type
18.14.2.3. By Application
18.14.2.4. By Drug Type
18.15. GCC Countries High Potency Active Pharmaceutical Ingredients Market Analysis
18.15.1. Value Proportion Analysis by Market Taxonomy
18.15.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.15.2.1. By Product Type
18.15.2.2. By Manufacturer Type
18.15.2.3. By Application
18.15.2.4. By Drug Type
18.16. South Africa High Potency Active Pharmaceutical Ingredients Market Analysis
18.16.1. Value Proportion Analysis by Market Taxonomy
18.16.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.16.2.1. By Product Type
18.16.2.2. By Manufacturer Type
18.16.2.3. By Application
18.16.2.4. By Drug Type
18.17. Turkey High Potency Active Pharmaceutical Ingredients Market Analysis
18.17.1. Value Proportion Analysis by Market Taxonomy
18.17.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.17.2.1. By Product Type
18.17.2.2. By Manufacturer Type
18.17.2.3. By Application
18.17.2.4. By Drug Type
18.17.3. Competition Landscape and Player Concentration in the Country
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Concentration
19.3. Market Share Analysis of Top Players
19.4. Market Presence Analysis
19.4.1. By Regional footprint of Players
19.4.2. Product footprint by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. BASF SE
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Sales Footprint
20.3.1.4. Strategy Overview
20.3.2. CordenPharma
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Sales Footprint
20.3.2.4. Strategy Overview
20.3.3. Dr. Reddy’s Laboratories Ltd.
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Sales Footprint
20.3.3.4. Strategy Overview
20.3.4. CARBOGEN AMCIS AG
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Sales Footprint
20.3.4.4. Strategy Overview
20.3.5. Pfizer, Inc.
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Sales Footprint
20.3.5.4. Strategy Overview
20.3.6. Sun Pharmaceutical Industries, Ltd.
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Sales Footprint
20.3.6.4. Strategy Overview
20.3.7. Teva Pharmaceutical Industries Ltd.
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Sales Footprint
20.3.7.4. Strategy Overview
20.3.8. Albany Molecular Research, Inc.
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Sales Footprint
20.3.8.4. Strategy Overview
20.3.9. Sanofi S.A.
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Sales Footprint
20.3.9.4. Strategy Overview
20.3.10. Merck & Co., Inc.
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Sales Footprint
20.3.10.4. Strategy Overview
20.3.11. Novartis AG
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Sales Footprint
20.3.11.4. Strategy Overview
20.3.12. F. Hoffmann-La Roche Ltd.
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Sales Footprint
20.3.12.4. Strategy Overview
20.3.13. Bristol-Myers Squibb Company
20.3.13.1. Overview
20.3.13.2. Product Portfolio
20.3.13.3. Sales Footprint
20.3.13.4. Strategy Overview
20.3.14. Boehringer Ingelheim International GmbH
20.3.14.1. Overview
20.3.14.2. Product Portfolio
20.3.14.3. Sales Footprint
20.3.14.4. Strategy Overview
20.3.15. Cipla Inc.
20.3.15.1. Overview
20.3.15.2. Product Portfolio
20.3.15.3. Sales Footprint
20.3.15.4. Strategy Overview
21. Assumptions and Acronyms Used
22. Research Methodology